TR201720642A2 - Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ - Google Patents
Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ Download PDFInfo
- Publication number
- TR201720642A2 TR201720642A2 TR2017/20642A TR201720642A TR201720642A2 TR 201720642 A2 TR201720642 A2 TR 201720642A2 TR 2017/20642 A TR2017/20642 A TR 2017/20642A TR 201720642 A TR201720642 A TR 201720642A TR 201720642 A2 TR201720642 A2 TR 201720642A2
- Authority
- TR
- Turkey
- Prior art keywords
- cafe
- guided
- microvesicular
- loaded
- improvement
- Prior art date
Links
- 239000003560 cancer drug Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 210000004927 skin cell Anatomy 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Bu buluş özelleşmiş deri hücrenin besi solüsyonuna bıraktığı mikrovesiküllere KAFE yüklemesi yapılarak SH-SY5Y nöroblastoma kanserine spesifik etkili bir ilaç üretimi ile ilgilidir. Buluşun amacı, doku hücrelerinin kültürü ve ardından özelleştirilmesi sonucunda elde edilen mikrovesiküllere KAFE yüklenerek hücreye spesifik güdümlü bir vesikül geliştirilmesinin ve tekniğin bilinen durumundaki uygulamalara kıyasla daha düşük konsantrasyonlarda KAFE kullanılmasıyla hem güdümlü olduğu hücreler dışındaki diğer hücrelere hem de vücuda yönelik toksisitesinin en aza indirgenmesinin sağlanmasıdır.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2017/20642A TR201720642A2 (tr) | 2017-12-18 | 2017-12-18 | Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ |
US16/955,087 US11510891B2 (en) | 2017-12-18 | 2018-12-17 | Cape-loaded targeted micro vesicular cancer drug and method for developing the same |
CA3086056A CA3086056A1 (en) | 2017-12-18 | 2018-12-17 | Cape-loaded targeted micro vesicular cancer drug and method for developing the same |
PCT/TR2018/050816 WO2019132831A2 (en) | 2017-12-18 | 2018-12-17 | Cape-loaded targeted micro vesicular cancer drug and method for developing the same |
EP18894456.5A EP3727590A4 (en) | 2017-12-18 | 2018-12-17 | TARGETED MICRO-VESICULAR ANTI-CANCER DRUG LOADED BY CAPE AND METHOD OF DEVELOPING THE SAME |
AU2018395740A AU2018395740B2 (en) | 2017-12-18 | 2018-12-17 | Cape-loaded targeted micro vesicular cancer drug and method for developing the same |
JP2020533249A JP2021508320A (ja) | 2017-12-18 | 2018-12-17 | Capeロードされた標的化微小胞抗がん剤およびその開発方法 |
RU2020123531A RU2785400C2 (ru) | 2017-12-18 | 2018-12-17 | Противораковое лекарственное средство в форме cape-нагруженных микровезикул направленного действия и способ его разработки |
CN201880089594.4A CN112020380A (zh) | 2017-12-18 | 2018-12-17 | Cape-装载的靶向微囊泡癌症药物及其开发方法 |
US17/840,700 US20220362194A1 (en) | 2017-12-18 | 2022-06-15 | Cape-loaded targeted microvesicular cancer drug and method for developing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2017/20642A TR201720642A2 (tr) | 2017-12-18 | 2017-12-18 | Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201720642A2 true TR201720642A2 (tr) | 2019-07-22 |
Family
ID=67066521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2017/20642A TR201720642A2 (tr) | 2017-12-18 | 2017-12-18 | Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ |
Country Status (8)
Country | Link |
---|---|
US (2) | US11510891B2 (tr) |
EP (1) | EP3727590A4 (tr) |
JP (1) | JP2021508320A (tr) |
CN (1) | CN112020380A (tr) |
AU (1) | AU2018395740B2 (tr) |
CA (1) | CA3086056A1 (tr) |
TR (1) | TR201720642A2 (tr) |
WO (1) | WO2019132831A2 (tr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
EP2240189B1 (en) * | 2008-01-04 | 2015-12-30 | Lydac Neuroscience Limited | Microvesicles |
WO2013012477A1 (en) * | 2011-05-20 | 2013-01-24 | New York University | Propolis and caffeic acid phenethyl ester and uses thereof |
US9801844B2 (en) * | 2012-05-24 | 2017-10-31 | The Research Foundation Of The City University Of New York | Methods and compositions for the treatment of cancer |
JP6542197B2 (ja) * | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
AU2015290284A1 (en) * | 2014-07-18 | 2017-01-19 | Manuka Health New Zealand Limited | Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health |
CN106692984B (zh) * | 2016-12-08 | 2020-02-18 | 武汉大学 | 一种基于细胞源性微囊泡的肿瘤靶向递送载体及制备方法和应用 |
-
2017
- 2017-12-18 TR TR2017/20642A patent/TR201720642A2/tr unknown
-
2018
- 2018-12-17 JP JP2020533249A patent/JP2021508320A/ja active Pending
- 2018-12-17 US US16/955,087 patent/US11510891B2/en active Active
- 2018-12-17 CN CN201880089594.4A patent/CN112020380A/zh active Pending
- 2018-12-17 WO PCT/TR2018/050816 patent/WO2019132831A2/en unknown
- 2018-12-17 EP EP18894456.5A patent/EP3727590A4/en active Pending
- 2018-12-17 AU AU2018395740A patent/AU2018395740B2/en active Active
- 2018-12-17 CA CA3086056A patent/CA3086056A1/en active Pending
-
2022
- 2022-06-15 US US17/840,700 patent/US20220362194A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021508320A (ja) | 2021-03-04 |
AU2018395740B2 (en) | 2024-02-15 |
US20210023038A1 (en) | 2021-01-28 |
AU2018395740A1 (en) | 2020-07-09 |
EP3727590A2 (en) | 2020-10-28 |
WO2019132831A3 (en) | 2019-09-26 |
RU2020123531A (ru) | 2022-01-20 |
CA3086056A1 (en) | 2019-07-04 |
WO2019132831A2 (en) | 2019-07-04 |
US20220362194A1 (en) | 2022-11-17 |
EP3727590A4 (en) | 2021-09-29 |
US11510891B2 (en) | 2022-11-29 |
CN112020380A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
EA201991369A1 (ru) | Модифицированные направляющие рнк | |
CY1125279T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
CY1120913T1 (el) | Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους | |
MX342735B (es) | Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. | |
EA201991555A1 (ru) | Композиции и способы усиления или увеличения продукции ifn i типа | |
MX2020011052A (es) | Proteinas biologicas condicionalmente activas. | |
GT201200322A (es) | Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica | |
EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
PE20120562A1 (es) | Anticuerpo anti-axl | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
EA201792635A1 (ru) | Устройство и способ культивирования тканей | |
MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
MX2021000295A (es) | Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon. | |
PE20170776A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
CY1116318T1 (el) | Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
CY1123489T1 (el) | Μεθοδοι θεραπειας του καρκινου με ημιζυγωτικη απωλεια του tp53 | |
EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
CY1117234T1 (el) | Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης | |
TR201720642A2 (tr) | Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ |